Clinical Trial Detail

NCT ID NCT03842228
Title Testing the Combination of the Anti-cancer Drugs Copanlisib, Olaparib, and MEDI4736 (Durvalumab) in Patients With Advanced Solid Tumors With Selected Mutations
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors National Cancer Institute (NCI)
Indications

Advanced Solid Tumor

Therapies

Copanlisib + Durvalumab + Olaparib

Age Groups: adult senior

Additional content available in CKB BOOST